HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody

Stock News09:50

HBM HOLDINGS-B (02142) saw its shares rise more than 8% during the morning trading session. At the time of writing, the stock was up 7.92%, trading at HK$13.21 with a turnover of HK$217.947 million. The surge follows an announcement on February 23 that the company has granted Solstice Oncology the global rights, excluding Greater China, for its next-generation CTLA-4 antibody HBM4003. Under the agreement, Solstice Oncology will pay over $105 million in upfront consideration, which includes a $50 million initial payment, a $5 million near-term payment, and company equity valued at over $50 million. Additionally, HBM HOLDINGS-B is eligible to receive up to $1.1 billion in milestone payments, along with tiered sales royalties. Public information indicates that Solstice Oncology is a clinical-stage biotechnology company founded by several leading venture capital firms, and this collaboration follows a NewCo model.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment